3种镇静方案用于孤独症患儿口腔治疗的效果研究

doi:10.13701/j.cnki.kqyxyj.2022.07.021

摘要/Abstract

摘要： 目的:探讨3种不同镇静方案在孤独症儿童牙科诊疗中的镇静效果。方法:选取Frankl量表评分为1分的孤独症谱系障碍患儿91例,随机分为3组:M1组29例,予肌注0.20 mg/kg咪达唑仑镇静;M2组33例,予肌注0.24 mg/kg咪达唑仑镇静;MD组29例,予肌注0.20 mg/kg咪达唑仑联合鼻喷2 μg/kg右旋美托咪定镇静。采用行为量表评估镇静效果。24 h后电话回访患儿不良反应及家长满意度。结果:所有患儿生命体征平稳,未出现严重不良反应。MD组镇静程度深于M1组(P<0.001)和M2组(P=0.004),M2组镇静程度深于M1组(P=0.047),镇静深度与镇静方案有关,与年龄、性别、治疗项目、口腔治疗史均无关。3组镇静成功率分别为31.0%、42.4%、65.5%,具有统计学差异(P=0.027)。治疗完成率差异没有统计学意义(P=0.616)。3组镇静起效时间分别为(15.148±2.429) min、(17.818±2.325) min、(20.571±4.167) min,具有统计学差异(P<0.001)。术后3组家长各有86.2%、90.9%、86.2%表示对镇静满意且下次就诊仍愿意选择镇静辅助治疗,均较镇静前持积极态度者增多。结论:对于孤独症患儿,3种镇静方案均有效。联合用药组镇静程度最深,镇静成功率最高,但镇静起效慢。

关键词: 孤独症谱系障碍, 咪达唑仑, 右旋美托咪定, 镇静, 儿童牙科

Abstract: Objective: To determine the effectiveness and safety of three different sedation methods on patients with autism spectrum disorder during dental treatment. Methods: Ninety-one autistic children were selected and randomly divided into three groups, i.e. group M1 (n=29), group M2 (n=33), and group MD (n=29). They received intramuscular midazolam in 0.2 mg/kg, 0.24 mg/kg, and 0.2 mg/kg with intranasal dexmedetomidine in 2 μg/kg for sedation, respectively. Sedation effectiveness was analyzed by behavioral rating scales. Telephone following-ups were performed 24 hours after treatment to record the side effects and parents' satisfaction. Results: Children's vital signs were stable and no severe complications occurred. The degree of sedation in group MD was the deepest (group M1 vs. group MD, P<0.001; group M2 vs. group MD, P=0.004; group M1 vs. Group M2, P=0.047). The sedation depth had no relationship with age, sex, treatment program, or history. The sedation success rates in three groups were 31.0% (group M1), 42.4% (group M2), and 65.5% (group MD), with a significant difference among them. There was no significant difference in the treatment completion rates among three groups. The satisfaction rates of parents were 86.2%, 90.9%, and 86.2%, which were higher than the acceptance rates before treatment. Conclusion: Intramuscular midazolam with or without intranasal dexmedetomidine was an effective sedation method in dental treatment of pediatric patients with autism spectrum disorder. Combination of intramuscular midazolam and intranasal dexmedetomidine was associated with the best sedation effectiveness and the highest sedation success rate but longest onset time, when compared to other two groups of intramuscular midazolam.

Key words: autism spectrum disorder, midazolam, dexmedetomidine, sedation, pediatric dentistry

杨格, 常惠惠, 陈婵婵, 丁桂聪. 3种镇静方案用于孤独症患儿口腔治疗的效果研究[J]. 口腔医学研究, 2022, 38(7): 682-686.

YANG Ge, CHANG Huihui, CHEN Chanchan, DING Guicong. Clinical Study on Efficacy of Three Different Sedation Methods in Dental Treatment of Autistic Children[J]. Journal of Oral Science Research, 2022, 38(7): 682-686.

参考文献

[1] Lord C, Elsabbagh M, Baird G, et al. Autism spectrum disorder [J]. Lancet, 2018, 392(10146):508-520.
[2] Mangione F, Bdeoui F, Monnier-Da Costa A, et al. Autistic patients: a retrospective study on their dental needs and the behavioural approach [J]. Clin Oral Investig, 2020, 24(5):1677-1685.
[3] Qiao Y, Shi H, Wang H, et al. Oral health status of Chinese children with autism spectrum disorders [J]. Front Psychiatry, 2020, 11:398.
[4] Kamat PP, McCracken CE, Simon HK, et al. Trends in outpatient procedural sedation:2007-2018 [J]. Pediatrics, 2020, 145(5):e20193559.
[5] Coté CJ, Wilson S. Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures [J]. Pediatr Dent, 2019, 41(4):259-260.
[6] Ohtawa Y, Yoshida M, Fukuda K. Parental satisfaction with Ambulatory Anesthesia during dental treatment for disabled individuals and their preference for same in future [J]. Bull Tokyo Dent Coll, 2019, 60(1):53-60.
[7] Kamat PP, Bryan LN, McCracken CE, et al. Procedural sedation in children with autism spectrum disorders: A survey of current practice patterns of the society for pediatric sedation members [J]. Paediatr Anaesth, 2018, 28(6):552-557.
[8] 聂娟,陈婵婵,谢静,等.口服与肌注咪达唑仑镇静治疗儿童牙科焦虑症的临床疗效对比[J].口腔医学研究,2021,37(2):148-152.
[9] Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients [J]. Eur J Clin Pharmacol, 1989, 37(3):267-272.
[10] Herrera MM, Campos LP, Hernández C, et al. Autism and paediatric dentistry: A scoping review [J]. Oral Health Prev Dent, 2019, 17(3):203-210.
[11] Delli K, Reichart PA, Bornstein MM, et al. Management of children with autism spectrum disorder in the dental setting: concerns, behavioural approaches and recommendations [J]. Med Oral Patol Oral Cir Bucal, 2013, 18(6):e862-e868.
[12] Li BL, Yuen VM, Zhang N, et al. A comparison of intranasal dexmedetomidine and dexmedetomidine plus buccal midazolam for non-painful procedural sedation in children with autism [J]. J Autism Dev Disord, 2019, 49(9):3798-3806.
[13] Lubisch N, Roskos R, Berkenbosch JW. Dexmedetomidine for procedural sedation in children with autism and other behavior disorders [J]. Pediatr Neurol, 2009, 41(2):88-94.
[14] Jo CW, Park CH, Lee JH, et al. Managing the behavior of a patient with autism by sedation via submucosal route during dental treatment [J]. J Dent Anesth Pain Med, 2017, 17(2):157-161.
[15] Chopra R, Mettal M, Bansal K, et al. Buccal midazolam spray as an alternative to intranasal route for conscious sedation in pediatric dentistry [J]. J Clin Pediatr Dent, 2013, 38(2) : 171-173.
[16] 景泉,万阔,赵继志.咪达唑仑口服镇静术辅助孤独症儿童口腔治疗研究[J].医学研究杂志,2009,38(11):49-52.
[17] Khrautieo T, Srimaneekarn N, Rirattanapong P, et al. Association of sensory sensitivities and toothbrushing cooperation in autism spectrum disorder [J]. Int J Paediatr Dent, 2020, 30(4): 505-513.
[18] 侯雪莹,万阔.儿童单纯口服咪达唑仑的药代动力学[J].协和医学杂志,2016,7(4):300-302.
[19] Riva A, Iapadre G, Grasso EA, et al. Intramuscular midazolam for treatment of status epilepticus [J]. Expert Opin Pharmacother, 2021, 22(1):37-44.
[20] Capp PL, de Faria ME, Siqueira SR, et al. Special care dentistry: Midazolam conscious sedation for patients with neurological diseases [J]. Eur J Paediatr Dent, 2010, 11(4):162-164.
[21] Stuker EW, Eskander JP, Gennuso SA. Third time's a charm: Oral midazolam vs intranasal dexmedetomidine for preoperative anxiolysis in an autistic pediatric patient [J]. Paediatr Anaesth, 2018, 28(4):370-371.
[22] Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats [J]. Anesthesiology, 1992, 76(6) : 948-952.
[23] Li A, Yuen VM, Goulay-Dufaÿ S, et al. Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine [J]. Br J Anaesth, 2018, 120(5):960-968.
[24] Li LQ, Wang C, Xu HY, et al. Effects of different doses of intranasal dexmedetomidine on preoperative sedation and postoperative agitation in pediatric with total intravenous anesthesia undergoing adenoidectomy with or without tonsillectomy [J]. Medicine (Baltimore), 2018, 97(39):e12140.
[25] De Cassai A, Boscolo A, Geraldini F, et al. Effect of dexmedetomidine on hemodynamic responses to tracheal intubation: A meta-analysis with meta-regression and trial sequential analysis [J]. J Clin Anesth, 2021, 72:110287.